Candel Therapeutics (NASDAQ:CADL) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Candel Therapeutics (NASDAQ:CADL - Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $19.00 price target on the stock. HC Wainwright also issued estimates for Candel Therapeutics' FY2025 earnings at ($1.39) EPS.

A number of other analysts have also recently weighed in on CADL. Citigroup began coverage on shares of Candel Therapeutics in a report on Thursday, February 20th. They issued a "buy" rating and a $25.00 price target on the stock. Bank of America began coverage on shares of Candel Therapeutics in a report on Friday, February 7th. They issued a "buy" rating and a $15.00 price target on the stock. Finally, Canaccord Genuity Group began coverage on shares of Candel Therapeutics in a report on Wednesday, February 19th. They issued a "buy" rating and a $20.00 price target on the stock.

Candel Therapeutics Stock Performance

Candel Therapeutics stock traded up $0.38 during midday trading on Wednesday, hitting $8.98. 695,391 shares of the company's stock were exchanged, compared to its average volume of 1,357,161. Candel Therapeutics has a 12 month low of $1.34 and a 12 month high of $14.60. The firm has a 50-day moving average of $8.35 and a two-hundred day moving average of $6.75. The company has a market cap of $291.63 million, a PE ratio of -5.19 and a beta of -1.25.

Insider Activity at Candel Therapeutics

In related news, CTO Seshu Tyagarajan sold 14,322 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the completion of the transaction, the chief technology officer now directly owns 96,790 shares of the company's stock, valued at $698,823.80. This trade represents a 12.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul B. Manning acquired 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The stock was bought at an average cost of $6.00 per share, with a total value of $7,500,000.00. Following the completion of the transaction, the director now directly owns 1,303,752 shares in the company, valued at $7,822,512. The trade was a 2,325.49 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 41,529 shares of company stock valued at $313,512 in the last three months. 41.60% of the stock is owned by insiders.

Institutional Trading of Candel Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in Candel Therapeutics during the 4th quarter valued at approximately $30,000. Russell Investments Group Ltd. lifted its stake in Candel Therapeutics by 75.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company's stock valued at $33,000 after acquiring an additional 1,610 shares during the period. FMR LLC acquired a new stake in Candel Therapeutics during the 3rd quarter valued at approximately $46,000. Wells Fargo & Company MN lifted its stake in Candel Therapeutics by 63.6% during the 4th quarter. Wells Fargo & Company MN now owns 10,122 shares of the company's stock valued at $88,000 after acquiring an additional 3,935 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Candel Therapeutics by 15.2% during the 4th quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company's stock valued at $90,000 after acquiring an additional 1,375 shares during the period. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.